Peri‑operative Hemoglobin Management in Sickle Cell Disease

Baseline Hemoglobin in Sickle Cell Disease

The chronic hemolytic anemia of sickle cell disease results in a steady‑state hemoglobin that is markedly lower than in the general population; these values represent a compensated baseline rather than an acute anemia that mandates immediate transfusion. 1

For patients undergoing surgery, the recommended target hemoglobin is approximately 10 g/dL (100 g/L), and a single transfusion episode should not raise hemoglobin by more than 4 g/dL (40 g/L) to avoid hyperviscosity. 2
In low‑risk surgical procedures where the pre‑operative hemoglobin is ≥ 9 g/dL (90 g/L), it is acceptable to proceed without a pre‑operative transfusion. 2
When the pre‑operative hemoglobin is < 9 g/dL, a simple top‑up transfusion to reach the 10 g/dL target is advised, provided this does not cause unacceptable surgical delay. 2
High‑risk surgeries or patients with significant comorbidities should receive a pre‑operative transfusion, often performed as an exchange transfusion to reduce HbS proportion while achieving the hemoglobin target. 2

Requirement	Details
HbS‑negative	Red blood cells must lack sickle hemoglobin to prevent further sickling.
ABO, Rh, Kell matching	Standard antigen compatibility to minimize alloimmunization.
Extended phenotype matching	Recommended when feasible to further reduce alloimmune risk.
Unit age	Simple transfusion units should be < 10 days old; exchange transfusion units should be < 8 days old.

All the above specifications apply to each transfused unit in the peri‑operative setting. 2

Attempting to raise hemoglobin to the normal healthy range (12–16 g/dL) in sickle cell patients can cause dangerous hyperviscosity and increase vaso‑occlusive complications; therefore, target levels should remain near the disease‑specific baseline. 2
Alloimmunization occurs in 7–30 % of individuals with sickle cell disease, complicating future transfusion therapy. 2

Some patients with the HbSC genotype may have resting hemoglobin values up to 12 g/dL; in such cases, a partial exchange transfusion to lower the HbS fraction can permit a higher target hemoglobin (above 10 g/dL) under expert guidance. 2

Sickle cell disease is an umbrella term that encompasses multiple genetic variants, all characterized by the presence of abnormal hemoglobin S (HbS) that causes red blood cells to sickle, according to the American College of Physicians 3, 4

Hemoglobin SS (HbSS) disease, also called sickle cell anemia, represents the most severe phenotype within sickle cell disease, characterized by severe anemia with typical hemoglobin levels of 60-90 g/L, as recommended by the American Society of Hematology 3, 5, 6
HbSS disease is associated with early onset of painful crises, 80-95% HbS with no normal adult hemoglobin (HbA) present, and a higher risk of complications including stroke, acute chest syndrome, and end-organ damage, as stated by the National Heart, Lung, and Blood Institute 3, 5, 7
Other forms like HbSC disease typically have higher baseline hemoglobin levels and generally fewer symptoms, though they still require careful management, according to the American Academy of Pediatrics 3, 5

The American College of Surgeons recommends that when encountering the term "sickle cell disease" in clinical practice, always determine the specific genotype (HbSS, HbSC, HbS β-thal, etc.) as this directly impacts disease severity and management 3, 5
HbSS patients require the most aggressive preventive measures perioperatively and have the highest complication rates, as advised by the Society of Critical Care Medicine 3, 5, 6
All forms of sickle cell disease share the common pathophysiology of HbS polymerization causing vaso-occlusion, hemolysis, and end-organ damage, according to the American Physiological Society 3, 7